Transforming Recruitment for Oncology Trials

iduneo's AI-powered platform transforms trial recruitment through two complementary channels: a direct-to-patient approach actively engages patients at home, and a hospital network integration that embeds trial options directly into the clinical workflows.

Access to clinical trial options in routine care and at home.

Explore treatment options

Patients

Most oncology guidelines recommend clinical trials as a vital therapeutic option, yet over 90% of patients remain unaware of this opportunity and miss the chance to participate. We bridge this gap by empowering patients to access clinical trials, identifying suitable options at the critical moment of therapeutic decision-making, and supporting them in their search for trials that align with their needs.

Our approach goes beyond simply highlighting trial opportunities. We thoroughly assess whether a patient is eligible for a specific trial, ensuring we only refer patients to trials for which they are fully qualified candidates. This precision maximizes patients' chances of accessing innovative treatments.

Offering innovative treatment options

Hospitals


Current recruitment methods are broken, with hospitals lacking both incentives and efficient processes to identify and refer suitable candidates.  Even for trials running at their hospital, recruiting requires the dedicated, case-by-case effort of individuals to overcome a variety of hurdles, making it an exception rather than the norm.

iduneo streamlines the entire patient identification and qualification journey from start to finish. We guide oncologists step-by-step, highlighting the actions needed to determine which trial is the best fit for each patient. 

We enable oncologists to promptly and effectively offer access to more and advanced therapies.

By enabling a decentralized qualification process for individual trials, we make non-research sites an integral part of advancing clinical research.

Developing Cancer Treatments

Life Sciences

Slow recruiting delays market access, costing pharma companies millions each day. iduneo's AI-powered platform transforms trial recruitment through two complementary channels: a direct-to-patient approach actively engages patients at home, and a hospital network integration that embeds trial options directly into the clinical workflows.

Through our dual approach we unlock previously untapped, but highly relevant patient populations in large second-tier hospitals and their regional referral networks for the life science industry. iduneo automates trial identification, raising awareness and overcoming qualification barriers, significantly increasing the number of enrolled patients.

Technology

Technology

The emergence of a new generation of AI offers new possibilities to overcome current challenges in clinical research. Our compound AI-system automates and simplifies the processes for patients and clinicians.

We are using an intelligent agent which streamlines the entire clinical trial matching process, from data extraction and intelligent pre-selection to detailed scoring and prioritization, enabling efficient patient qualification even in the clinical everyday routine.

Through our hybrid solution combining AI-matching, AI-guidance for patient qualification, and patient centered services, iduneo is scaling patient recruitment in new ways.

Our Mission: Accelerate Clinical Trials

About us


Driven by our extensive experience and passion for clinical research, we've tailored our approach to meet the needs of both our patients and industry partners.

Our team has over 40 years of combined expertise in clinical research, patient recruitment, trial site operations, and data analytics, gathered at leading pharmaceutical companies, renowned research institutions, and major clinical trial networks.

At iduneo, we merge AI-driven solutions with deep medical knowledge to bridge the gap between clinical research and patient care. We empower patients to access clinical trials as an additional treatment option while helping pharmaceutical companies accelerate the delivery of new therapies to market.